Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...

Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an “important” weight loss treatment.

Lexicon Pharmaceuticals (LXRX) stock soars as the company inks a licensing deal worth up to $1B with Novo Nordisk (NVO) for ...

Novo Nordisk has licensed an oral obesity drug that works via an uncommon mechanism and may help patients maintain their ...

Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. | Lexicon Pharmaceuticals ...

Drugs like Ozempic, Wegovy, and Saxenda have become hugely popular. But could they cause psychological side effects in their ...

As artificial intelligence continues to evolve, especially here in the Bay Area, one lab is working to use AI technology to find the next effective weight loss drug.

Drugs like Ozempic and Wegovy have the power to block the forces driving obesity, but the knock-on societal effects may not ...

GLP-1 drugs have revolutionised the treatment of obesity, but the very reason they are effective is also why it's vital to ...

MIT scientists have created a method to "paint" GLP-1 drugs onto antibodies inside the body, achieving longer-lasting effects ...

Not sure how to find NewsNation on your TV? Find your channel here. Get 24/7 fact-based unbiased news coverage with the NewsNation app. On DOGE’s website, it claims that $115 billion has saved ...

How you add protein to the diet decides how quickly you lose weight without affecting health. Protein plays a crucial role in weight loss by promoting satiety, preserving muscle mass, and boosting ...